Skip to main content
spacbrain

Apollomics

Closed (deSPAC)

Health Care · clinical-stage biopharmaceutical company

What it is
A private company in health care preparing to list via a SPAC merger. Full profile in progress.
What it’s doing now
Merging with Maxpro Capital Acquisition Corp. (JMAC) — closed (despac).
What you should know
Data is still being assembled for this company — what is shown below is everything we have verified so far.
Profile in progress — we only publish what we can verify in filings, and for this company that work isn’t finished. Identity and deal facts above are current; business detail, financials and peers will appear as the filings are parsed.

What the company says about itself

Web research — not audited

Apollomics Inc. is a company focused on combating pan-cancer with precision by basing clinical trials on sound mechanistic and scientific rationale. Their pipeline includes multiple targeted therapies that harness the immune system and target specific molecular pathways. The name is derived from the Greek verb 'apollymi' (to destroy) and 'omics', reflecting their mission to utilize scientific rationale to eradicate cancer.

Markets:
Oncology | Clinical Trials | Biotechnology
Products:
Targeted therapies
What our web check found

[WEB-INTEL 2026-08-26] 13 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The business combination is expected to close in the first quarter of 2023 and Apollomics is expected to be listed on Nasdaq under the ticker" [https://www.apollomicsinc.com/updates/apollomics-inc-a-late-stage-clinical-biopharmaceutical-company-to-be-listed-on-nasdaq-through-business-combination-with-maxpro-capital-acquisition-corp/] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The companies announced plans to merge in September 2022, with the deal valuing Apollomics at $899M." [https://seekingalpha.com/news/3952884-apollomics-stock-ends-debut-session-172-percent-higher] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Apollomics has raised $233.9M across 3 funding rounds. Most recently, it raised $124.2M Series C in November 2020." [https://startupintros.com/orgs/apollomics] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Apollomics has raised a total funding of $244M over 5 rounds. Its first funding round was on 2016." [https://tracxn.com/d/companies/apollomics/__pOrqNLnClS3aWj4K7MM0QvhlZEwZr87F269Pg7v7otk] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Apollomics has raised $250M across disclosed rounds through Series C." [https://startupfundraising.com/how-much-has-a-company-raised/apollomics] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "approximately $10.0 million. close on or about August 14, 2026, proceeds of approximately" [https://ir.apollomicsinc.com/news-releases/news-release-details/apollomics-announces-10-million-private-placement-transaction] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Apollomics is raising aggregate gross consideration of approximately $10.0 million through the issuance of up to 700,001 Class A ordinary shares" [https://www.stocktitan.net/sec-filings/APLM/6-k-apollomics-inc-current-report-foreign-issuer-6a98a731e231.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Private placement gross proceeds: $10.0 million" [https://www.stocktitan.net/sec-filings/APLM/6-k-apollomics-inc-current-report-foreign-issuer-6a98a731e231.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Shares to be issued: 700,001 Class A ordinary shares" [https://www.stocktitan.net/sec-filings/APLM/6-k-apollomics-inc-current-report-foreign-issuer-6a98a731e231.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Par value per share: $0.01 per share" [https://www.stocktitan.net/sec-filings/APLM/6-k-apollomics-inc-current-report-foreign-issuer-6a98a731e231.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "UNAFFILIATED INVESTOR CASH TRANCHE 283,344 Class A ordinary shares" [https://www.stocktitan.net/sec-filings/APLM/6-k-apollomics-inc-current-report-foreign-issuer-6a98a731e231.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The transaction is expected to close on or about August 14, 2026, subject to customary conditions." [https://www.stocktitan.net/sec-filings/APLM/6-k-apollomics-inc-current-report-foreign-issuer-6a98a731e231.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "it had received $4.1 million PIPE investments from certain investors" [https://www.globenewswire.com/news-release/2025/10/14/3165856/0/en/apollomics-inc-company-operational-continuity-update.html]

Source: https://www.apollomicsinc.com/ · captured Aug 26, 2026 · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

Apollomics is merging with Maxpro Capital Acquisition Corp. (JMAC) currently marked Closed (deSPAC).

Headline equity value—

How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is Apollomics going public?

Apollomics has an approved merger with the SPAC Maxpro Capital Acquisition Corp. (JMAC). Deal status: Closed (deSPAC).

Does Apollomics have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.

Other health care deals